Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies

Marinos C Dalakas

Nature Clinical Practice Rheumatology (2006) **2**: 219–227 [doi:10.1038/ncprheum0140]

doi:10.1038/ncprheum0220

CORRIGENDUM

In the April 2006 issue, the following sentence was published in the final paragraph of the above article by Marinos C Dalakas “Such semispecific immunotherapies could be accomplished with monoclonal antibodies that affect T-cell

regulatory pathways, such as anti-CD56 (alemtuzumab)...”. This sentence should have appeared as “Such semispecific immunotherapies could be accomplished with monoclonal antibodies that affect T-cell regulatory pathways, such as anti-CD52 (alemtuzumab)...”.